Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,326 recruiting studies in this area right now.
By phase
- Not applicable9,607
- Phase 24,435
- Phase 12,680
- Phase 1/Phase 21,650
- Phase 31,400
- Phase 2/Phase 3286
- Phase 4268
Top conditions
- Breast Cancer1,207
- Prostate Cancer648
- Cancer636
- Colorectal Cancer478
- Lung Cancer420
- Ovarian Cancer340
- Multiple Myeloma329
- Pancreatic Cancer289
- Gastric Cancer285
- Acute Myeloid Leukemia283
- Hepatocellular Carcinoma258
- Solid Tumor246
- Advanced Solid Tumor232
- Head and Neck Cancer229
- Cervical Cancer225
- Endometrial Cancer213
- Advanced Solid Tumors207
- Esophageal Cancer192
Leading sponsors
- M.D. Anderson Cancer Center455
- Fudan University305
- National Cancer Institute (NCI)293
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University275
- Mayo Clinic236
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences145
- AstraZeneca132
- Ruijin Hospital128
Where studies are running
- California1,402
- Texas632
- Arizona505
- Florida437
- Alabama430
- New York404
- Massachusetts340
- Maryland331
- New Jersey275
- Pennsylvania236
Recruiting studies20,326 total
- NCT05292521Recruiting
Quality-of-life program to help early lung cancer decisions
This trial tests a quality-of-life support program meant to help people with early-stage lung cancer think through their treatment choices. It may help you feel more informed and more confident about deciding between treatments like surgery and SBRT.
Buffalo, New YorkAges 18 years+ - NCT05617716RecruitingPhase 2
Spine radiosurgery for painful cancer spread to the spine
This Phase 2 study tests a precise radiation treatment (spine SBRT, also called radiosurgery) to reduce pain from cancer that has spread to the spine. It focuses on people with stable spine structure and low pain at the start, to see how well the treatment works and stays safe.
Baltimore, MarylandAges 18 years+ - NCT05426928Recruiting
Study of body heat modeling during HIPEC surgery
This trial studies how the body’s heat changes during HIPEC surgery for abdominal cancer. It may help improve how doctors plan and deliver HIPEC in the future.
Detroit, MichiganAges 18 years+ - NCT02848274Recruiting
Looking for factors that predict outcomes in advanced skin lymphoma
This study looks at medical and disease details to find factors that can help predict how advanced mycosis fungoides or Sézary syndrome will behave. Your information may help doctors better estimate prognosis and plan care.
Duarte, CaliforniaAges Any age - NCT03830801Recruiting
Testing laser-guided sampling to predict Barrett’s esophagus risk
This study checks whether a special laser-guided method can safely collect tiny tissue samples from the esophagus to help predict how Barrett’s esophagus may turn out. If you have Barrett’s, the results may help doctors better estimate your future risk.
Boston, MassachusettsAges 18 years+ - NCT05512208RecruitingPhase 2
Avutometinib plus defactinib for RAS or BRAF mutated gynecologic cancer
This Phase 2 trial tests a two-drug treatment (avutometinib plus defactinib) for certain advanced gynecologic cancers that have specific cancer-driving DNA changes (like RAS or BRAF). It’s designed for people whose cancer has returned or gotten worse after at least one prior treatment for metastatic disease.
Orlando, FloridaAges 18–99 - NCT06102902RecruitingPhase 1
New drug added to chemotherapy for BRAF-mutated colorectal cancer
This trial combines a new drug called ZEN003694 with two standard chemotherapy drugs (cetuximab and encorafenib) to see if it can help people with a specific type of colorectal cancer that has the BRAF V600E mutation. This mutation makes the cancer grow, and the new drug targets it, potentially making the treatment more effective.
Costa Mesa, CaliforniaAges 18 years+ - NCT06096870RecruitingPhase 2
Enzalutamide with a new drug for prostate cancer that is active on PET scan
This trial tests a combination of enzalutamide (a hormone blocker) and an investigational antibody-drug (PDS01ADC) in men whose prostate cancer has come back after initial treatment, but has not yet spread extensively. It does not involve standard hormone therapy that lowers testosterone.
Bethesda, MarylandAges 18–120 - NCT06103838RecruitingPhase 2
Fluciclovine PET/CT scan for multiple myeloma
This trial tests whether a special PET/CT scan (using fluciclovine, a radioactive tracer) can more clearly see multiple myeloma in the body. It may help doctors evaluate the extent of the disease and guide treatment decisions.
Bethesda, MarylandAges 18–120 - NCT06084338RecruitingPhase 2
Focused Radiation Therapy Without Hormone Therapy for Advanced Prostate Cancer
This trial tests whether giving focused radiation to many cancer spots (SBRT) can work without using testosterone-blocking hormone therapy. It is for men whose prostate cancer has spread and is no longer responding to low testosterone, and who have already tried one of the newer hormone drugs.
West Los Angeles, CaliforniaAges 18 years+ - NCT06081920RecruitingPhase 2
IBI363 for advanced melanoma after standard treatment
This study tests a new drug called IBI363 for people with advanced melanoma that has progressed after standard treatment. It aims to see if IBI363 can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06098560Recruiting
ctDNA as a marker for immunotherapy in advanced colorectal cancer
This study looks at whether a blood test for tumor DNA (ctDNA) can predict how well immunotherapy works in people with advanced or locally advanced colorectal cancer that has specific genetic features (dMMR/MSI-H). If you qualify, the trial will monitor your ctDNA levels while you receive standard immunotherapy to see if changes in those levels can show early on if the treatment is working.
Beijing, Beijing MunicipalityAges 18–80 - NCT06087653RecruitingPhase 1/Phase 2
Continuous lenalidomide shot for multiple myeloma
This trial tests a new way to give lenalidomide (Revlimid) as a continuous shot under the skin (subcutaneous infusion) for people with multiple myeloma that has come back or not responded after at least one prior treatment. The goal is to see if this method works better and is easier to tolerate than the standard pill form.
Wilson, North CarolinaAges 18 years+ - NCT06084936RecruitingPhase 3
Glofitamab alone vs other treatments for mantle cell lymphoma
This trial tests a new drug called glofitamab to see if it works better than other standard treatments for people with mantle cell lymphoma that has come back or not responded to previous therapy. It is for patients who have already tried a BTK inhibitor and at least one other treatment.
Berkeley, CaliforniaAges 18 years+ - NCT06097156Recruiting
Automated blood test for breast cancer monitoring
This trial tests an automated device that prepares blood samples to detect cancer-related changes. It aims to improve how doctors monitor breast cancer that has spread, without needing a tissue biopsy every time.
MilanAges 18 years+ - NCT06081959RecruitingPhase 3
Study of SKB264 for advanced HR+/HER2- breast cancer
This trial tests a new drug called SKB264 for people with a common type of breast cancer (HR+/HER2-) that has spread or come back and has not responded to at least one round of chemotherapy. It aims to see if this treatment can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06097962RecruitingEarly Phase 1
NK510 cell therapy for advanced lung cancer after immunotherapy
This trial tests a new natural killer (NK) cell therapy, NK510, for people with advanced non-small cell lung cancer who have already tried immunotherapy and it stopped working. The goal is to see if NK510 is safe and can shrink tumors or slow the cancer's growth.
Nanjing, JiangsuAges 18 years+ - NCT06103864RecruitingPhase 3
Study of Dato-DXd with or without durvalumab for advanced triple-negative breast cancer
This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.
Daphne, AlabamaAges 18 years+ - NCT06088004RecruitingPhase 1/Phase 2
ABO2011 for advanced solid tumors (phase 1/2)
This trial tests a new investigational drug called ABO2011, which is injected directly into tumors. It is for people with advanced solid tumors that have not responded to previous treatments. The goal is to see if the drug is safe and can help shrink or slow tumor growth.
BeijingAges 18 years+ - NCT06085833Recruiting
Using ARTIDIS to measure early breast lesions
This trial tests a new device called ARTIDIS that measures the stiffness of breast tissue to help identify early breast lesions. It may provide a noninvasive way to assess breast health.
Dallas, TexasAges 18 years+ - NCT06095505RecruitingPhase 2
Alisertib for extensive stage small cell lung cancer
This trial tests a new drug called alisertib for people with small cell lung cancer that has spread. It is for those who have already tried standard treatments (chemotherapy and immunotherapy) and need another option.
Daphne, AlabamaAges 18 years+ - NCT06084481RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
Duarte, CaliforniaAges 18 years+ - NCT06093672RecruitingPhase 3
Comparing givinostat vs hydroxyurea for polycythemia vera
This study compares a new drug called givinostat to hydroxyurea (a standard treatment) for people with polycythemia vera, a blood disorder that increases the risk of clots. The goal is to see if givinostat works better and is safe.
Birmingham, AlabamaAges 18 years+ - NCT06104371Recruiting
Magnetic markers to find lymph nodes before chemo for breast cancer
This trial tests a new method using magnetic markers (Magtrace and Magseed) to find lymph nodes before chemotherapy. It may help doctors better target the lymph nodes that need to be removed during breast cancer surgery.
GothenburgAges 18–85
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,326 recruiting oncology studies from the U.S. registry right now, out of 31,457 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.